株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品のブラジル市場展望:2016-2026年

Brazilian Pharmaceutical Market Outlook 2016-2026: Revenue Forecasting of Originator, Generis & OTC Medicines & Therapy Areas Including CNS, Cardiovascular & Cancer, Exploration of Regional Differences in Healthcare, Discussion of Domestic Manufacturers

発行 Visiongain Ltd 商品コード 290179
出版日 ページ情報 英文 192 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.80円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬品のブラジル市場展望:2016-2026年 Brazilian Pharmaceutical Market Outlook 2016-2026: Revenue Forecasting of Originator, Generis & OTC Medicines & Therapy Areas Including CNS, Cardiovascular & Cancer, Exploration of Regional Differences in Healthcare, Discussion of Domestic Manufacturers
出版日: 2016年09月05日 ページ情報: 英文 192 Pages
概要

ブラジルの医薬品市場は2020年に311億米ドルに達すると予測されています。2016年ら2026年まで目覚ましい成長を続ける見通しです。

当レポートは、ブラジルの医薬品市場について調査し、国レベル・2次市場における収益の予測、国内・海外のディベロッパー・メーカー・販売業者の見通し、および市場の促進因子・阻害因子の分析などをまとめ、お届けいたします。

第1章 調査概要

第2章 ブラジルの医薬品市場:イントロダクション

  • ブラジルの医薬品市場概要
  • ジェネリック医薬品区分は引き続き重要性を増す
  • CNS (中枢神経系) は最大の治療領域
  • 国内企業4社がトップ10に

第3章 ブラジル市場の重要性

  • 世界で第9位のブラジル経済
  • 世界第8位の医薬品市場
  • ラテンアメリカ最大の医薬品市場
  • ブラジルは医薬品新興国市場 (Pharmerging) およびBRIC市場の一部

第4章 ブラジル医薬品市場の組織

  • ANVISA:FDAに相当するブラジルの主要な組織
  • その他の有力な機関
  • SUS (統一保健医療システム):世界最大の公的医療制度の一つ
  • 人口の25%が民間医療機関を利用
  • 民間保健市場の成長、しかし保険業者のコストは上昇
  • 新薬価調整制度の導入
  • リネーム医薬品および薬局 (Farmacia) が人気
  • ブラジルの薬局の緊密なネットワーク
  • 卸売および小売部門の統合が進行中
  • Panpharmaは卸売最大手
  • 最大の混合卸売会社、Profarma
  • Raia Drogasilは小売部門のリーダー
  • ブラジルにおけるマーケティング支出は50億米ドルに近付く

第5章 ブラジルの地域間で多様な医療

  • 人口、医薬品市場のシェアおよびGDP:地域別
  • 南東部:人口の42%、医薬品収益の53%
  • 南部:最も小さい地域、しかし二番目に高いGDP
  • 北東部:2番目に高い医薬品市場シェア、しかし国民1人あたりのGDPは最も低い
  • 北部:最も大きく最も貧しい地域、医薬品市場の5%以下
  • 中西部:首都を抱える内陸地域、人口は最も少ない

第6章 ブラジルの医薬品市場の内訳:製品別

  • 市場の特許処方薬、ジェネリック医薬品およびOTC区分の予測
  • オリジナル製薬部門はジェネリック医薬品に追い越される見通し
  • ジェネリック医薬品区分の予測
  • ブラジルの生物製剤市場
  • OTC区分の予測

第7章 ブラジル市場における治療領域

  • CNS、心血管、消化管/代謝、がん、感染症およびその他の治療領域
  • 非伝染性疾病の増加
  • CNS疾患市場の予測
  • 心血管治療領域の市場予測
  • 消化管/代謝治療領域の予測
  • がん治療薬市場の予測
  • 感染症治療領域の予測
  • その他の治療領域

第8章 ブラジル市場における国内企業

  • ブラジルにおける医薬品企業の上位10社
  • 多国籍企業が依然として市場の大部分を支配
  • 政府の奨励により活発な国内部門
  • 国内企業がジェネリック医薬品市場の70%を支配
  • EMS:ブラジル最大の医薬品企業
  • Hypermarcas:OTCおよびブランドジェネリック医薬品のリーダー
  • Medley:Sanofi傘下のジェネリック医薬品企業
  • Ache:ブラジル最大の買収対象
  • Eurofarma:ラテンアメリカの90%を占める農園を持つ国内5番目企業
  • Teuto:ラテンアメリカ最大の製薬複合企業を運営
  • Biolab Farmaceutica:心臓病治療薬の最大手
  • Cristalia:ラテンアメリカ最大の麻酔薬メーカー
  • Libbs:癌治療における中心的存在
  • Uniao Quimica:巨大な年間生産能力を持つ
  • Laboratorio Daudt Oliveira および Hebron など、その他の国内企業
  • バイオシミラーとのコラボレーション

第9章 ブラジル市場における多国籍企業

  • ブラジルにおける多国籍医薬品企業の上位10社
  • 注目すべきM&A活動
  • Sanofi
  • Novartis
  • Roche
  • Merck & Co.
  • Pfizer
  • 武田薬品工業
  • Bayer
  • AstraZeneca
  • Boehringer Ingelheim
  • Merck KGaA
  • その他の有力な多国籍企業
  • 多国籍企業の主要なジェネリック医薬品はブラジルで競合できるか
  • 医薬品研究先としてのブラジル

第10章 ブラジルの医薬品市場の定性分析

  • SWOT分析(強み、弱み、機会および脅威)
  • STEP分析(社会的、技術的、経済的および政治的要因)

第11章 調査インタビュー

第12章 調査・分析の結論

  • ブラジル市場の成長はその他の先進諸国を凌駕する勢い
  • ジェネリック医薬品は最も急成長する区分となる見込み
  • 技術移転が国内の創薬を後押し
  • ジェネリック医薬品:多国籍企業に代替オプションを提供
  • がん治療:最大の治療・商業機会
  • 結論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0140

Title:
BRAZILIAN PHARMACEUTICAL MARKET OUTLOOK 2016-2026
Revenue Forecasting of Originator, Generic and OTC Medicines and Therapy Areas Including CNS, Cardiovascular and Cancer; Exploration of Regional Differences in Healthcare; Discussion of Domestic Manufacturers Including EMS, Hypermarcas and Aché, and International Drug Companies Including Sanofi, Novartis and Roche.

Medicine Sales in Brazil - How to Find Trends, Opportunities and Forecasted Revenues

Do you want to assess Brazil's pharmaceutical market from 2016? If so, visiongain's new report gives you revenue forecasts, helping your research and analysis. That study's purpose is to show opportunities, trends and sales predictions to 2026.

Brazil can satisfy expectations for wider healthcare coverage and rapid expansion of its pharma industry and market. With our updated study you explore business analysis, developments and opportunities for domestic and foreign companies.

Please read on to explore Brazilian medical sales and see how high that fast developing country's revenues could go.

Trends and outlooks for that emerging healthcare market - what is possible?

From 2016 patients, treatment providers and the pharmaceutical industry will benefit from progress in Brazilian healthcare. Discover in our study what the future holds - medical needs and potential revenues. Also find rankings of companies.

Our new analysis shows you revenue predictions from 2016 to 2026 at overall national and submarket levels. You discover the most lucrative parts of that country's drug market, seeing opportunities to benefit patients, healthcare providers and pharma companies. Explore what the future holds for domestic producers and multinational pharma companies.

Forecasts and other data help you find where the money lies in Brazil's medical sales

To support our forecasting, our work shows you historical results, sales growth rates and market shares. In our 191 page report you gain 52 tables, 55 charts and interviews with representatives from BiocadBrazil Farmaceutica and Sandoz Brazil.

With our study, see how you could save time and avoid struggles to find data to help your research, analysis, plans and presentations. See, too, how you could help your influence, benefiting your reputation for commercial insight on Brazilian pharma.

The following sections show how our investigation helps your work.

Potential of Brazil's drug sales - overall market and segment forecasts

What is Brazil's potential as a pharma market? In our analysis you discover overall revenues to 2026, with discussions. Our report also shows you individual sales predictions - from 2016 to 2026 - for three main submarkets:

  • Patented therapies - original brands of prescription drugs
  • Generic pharmaceuticals (generics)
  • OTC medicines - over-the-counter treatments.

The future looks promising for Brazilian pharmaceutical sales. That developing national market is growing at a faster rate than more-mature markets, and can continue to do so over the next ten years. See what is possible.

With our study also extend your knowledge of that country's medical needs and pharma industry. In addition you explore forecasting for therapeutic applications, assessing demand and potential revenues.

Diseases and their treatment - what prospects for drugs and their sellers?

Our new study also predicts revenues in Brazil for treating prominent diseases. See individual revenue forecasts to 2026 for six therapeutic categories:

  • Central nervous system (CNS)
  • Cardiovascular (CV)
  • Gastrointestinal and metabolic
  • Cancer treatments (oncology)
  • Infectious diseases - anti-infective agents (vaccines and antibiotics)
  • Therapies for other disorders (grouped analysis).

How fast will those submarkets expand? How high will their revenues go? With our report you assess opportunities and potentials, seeing what developments and sales are possible.

There you also investigate what stimulates and restrains sales of drugs.

Issues and events in Brazil - what affects drug developers, producers and sellers?

Our study discusses forces affecting Brazil's medical sales from 2016, including these influences:

  • Efforts of companies and public healthcare providers to serve patients' needs
  • Strategies of domestic and foreign companies, including mergers and acquisitions (M&A), drug launches, sales ranking and Brazilian market share
  • Trends in demographics, economics and epidemiology - assess medical needs, including Zika virus infection
  • Wholesalers, distributors and retailers of medicines - the supply chain
  • Governmental policies - explore activities of ANVISA and SUS and other bodies - including the new drug price adjustment system, the RENAME reimbursement programme and ANVISA reform of patent protection.

With our study you also assess these influences, among others:

  • Efforts by regions to improve medical provision, better serving populations
  • Healthcare insurance - public and private - to improve access to medicines
  • Technologies - competitors' research and development and manufacturing
  • Technology transfer and IP protection, including action against counterfeiting
  • Rising demand for biological drugs, including biosimilars
  • Brazil's position in overall world, Latin American, BRIC nations and pharmerging countries' pharmaceutical markets.

With our analysis you examine political, economic, social and technological questions, assessing commercial prospects. You also investigate strengths, weaknesses, opportunities and threats.

Explore what stimulates and restrains domestic and foreign pharmaceutical companies in Brazil, discovering what is possible from 2016 to 2026.

Analysis of top companies and their industry - what future sales are possible?

What happens next? Our work predicts the Brazilian pharma market will reach $31.1bn in 2020 - with strong expansion from 2016 to 2026. See what is possible.

In our report you discover what causes that sales growth and why Brazil attracts and develops pharma business. There you explore activities of 10 leading domestic companies and other firms, including these organisations:

  • EMS
  • Hypermarcas
  • Aché
  • Eurofarma
  • Cristália
  • Libbs
  • União Química.
  • You also assess 10 multinational - big pharma - organisations and other foreign players operating there, including these corporations:
  • Sanofi
  • Novartis
  • Roche
  • Pfizer
  • Takeda
  • Bayer
  • Merck & Co.

You also see interviews with BiocadBrazil Farmaceutica and Sandoz Brazil. Discover the efforts of pharma specialists, including firms making biopharmaceuticals. From 2016 many firms stand to gain.

Leading generic and biosimilar drug developers, producers and sellers

In our report you assess other international manufacturers and marketers of drugs for Brazil, including generics and biosimilars:

  • Teva Pharmaceutical Industries
  • Mylan
  • Actavis
  • Daiichi Sankyo
  • Glenmark
  • Valeant
  • Strides Arcolab
  • Biocon.

Pharma industry leaders and specialty companies will expand their operations and sales there. Explore what is possible in Brazil and see how you could benefit.

5 ways Brazilian Pharmaceutical Market Outlook 2016-2026 helps your work

In these five main ways, our investigation gives knowledge to benefit your research, analyses and decisions:

  • Brazil's overall pharma revenues from 2016 - discover that leading developing country's prospects for medical investments, marketing and sales
  • Submarkets' revenues to 2026 - investigate 9 segments at national level, finding product groups and therapeutic needs with highest potential revenues
  • Prospects for domestic and foreign drug developers, producers and sellers - explore portfolios, R&D, product approvals, collaborations, M&A and outlooks
  • Opinion and news from companies - see views to help you stay ahead in knowledge, including two interviews
  • Analysis of what stimulates and restrains Brazil's market for human medicines - assess challenges and strengths there, helping you compete and gain advantages.

That study, by our in-house analysts in the UK, gives data to benefit your work. Our survey shows information you find nowhere else, helping you stay ahead.

Independent analysis showing you the potential of Brazil's pharma sales

Our report gives analysis showing you the most promising opportunities. Discover progress and possibilities for pharmaceutical sales in Brazil.

Through choosing our study, see how you could save time and effort, also benefiting your authority and reputation for commercial insight.

Our investigation is for everyone analysing rising and emerging pharma markets. Brazil holds great commercial potential - our study shows you trends, forecasts and discussions to help you stay ahead in knowledge. So avoid missing out - please get our new report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Brazil: Pharmaceutical Market Overview
  • 1.2. Brazilian Pharmaceutical Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Main Questions Answered by This Survey
  • 1.6. Who is Our Report For?
  • 1.7. Research and Analysis Methods
  • 1.8. Frequently Asked Questions (FAQs)
  • 1.9. Some Associated Reports
  • 1.10. About Visiongain

2. Introduction to the Brazilian Pharmaceutical Market

  • 2.1. The Brazilian Pharmaceutical Market Overview
  • 2.2. Generics Segment Continues to Grow in Importance
  • 2.3. CNS - The Largest Therapeutic Area in 2015
  • 2.4. Four Domestic Companies in the Top Ten in 2015

3. The Significance of the Brazilian Market

  • 3.1. Brazilian Economy is the Ninth Largest in the World
  • 3.2. Brazil is the Eighth Largest Pharmaceutical Market
  • 3.3. Brazil is the Largest Market in Latin America
  • 3.4. Brazil Qualifies as a ‘Pharmerging' Country and one of the BRIC Markets

4. Organisation of the Brazilian Pharmaceutical Market

  • 4.1. ANVISA - Brazil's Equivalent of the FDA
  • 4.2. Other Influential Organisations
  • 4.3. SUS - One of the World's Largest Public Health Systems
  • 4.4. Private Healthcare Accessed by 25% of the Population
  • 4.5. Private Insurance Market Growing but Costs are Rising
  • 4.6. New Drug Price Adjustment System Introduced
  • 4.7. RENAME Drug Reimbursement System and the Farmácia Popular
  • 4.8. Extensive Network of Pharmacies in Brazil
  • 4.9. Wholesale and Retail Sectors Undergoing Consolidation
  • 4.10. Panpharma is the Top Wholesale Distributor
  • 4.11. Profarma is the Largest Mixed Distributor
  • 4.12. Raia Drogasil is the Leader in the Retail Sector
  • 4.13. Spending on Marketing Approaches $5bn

5. Major Differences in Healthcare Between Regions

  • 5.1. Size and Prosperity of Different Regions
  • 5.2. South-East is the Richest and Most Populous Region
  • 5.3. South Has the Second Highest GDP
  • 5.4. North-East Has the Second Highest Pharmaceutical Market Share
  • 5.5. North is the Largest and Poorest Region
  • 5.6. Mid-West is a Landlocked Region Housing the Nation's Capital

6. Product Segments in the Brazilian Pharmaceutical Market 2016-2026

  • 6.1. Forecasts for the Originator, Generic and OTC Segments 2015-2026
  • 6.2. Originator Segment Will be Overtaken by Generics
    • 6.2.1. Product Development Partnerships to Reduce Costs
    • 6.2.2. Originator Drugs Threatened by 35% Cheaper Generics
  • 6.3. Generics Drug Segment Forecast 2015-2026 - Continued Rapid Growth
    • 6.3.1. Rapid Expansion of Generic Segment
    • 6.3.2. Generic Companies Aiming for 45% Market Share
    • 6.3.3. Similares Drugs Face Same Pricing Rules as Generics
    • 6.3.4. Counterfeit Drugs Account for 20% of the Market
    • 6.3.5. National Drug Security System to Tackle Counterfeit Drugs
    • 6.3.6. Challenges for the Brazilian Generics Market
  • 6.4. Brazilian Biologics Market
    • 6.4.1. Biosimilars Market to Double in Size by 2017
    • 6.4.2. BiocadBrazil Brings More Biosimilars to Brazil
  • 6.5. OTC Drug Segment Forecast 2015-2026
    • 6.5.1. Analgesics and Multivitamins Favoured by Brazilians
    • 6.5.2. One Sixth of Population Buy Multivitamins
    • 6.5.3. Restrictions on OTC Products Reversed
    • 6.5.4. Consumer Health Treatments Remain Prominent in the Market

7. Therapeutic Areas of the Brazilian Market 2015-2026

  • 7.1. Forecasts for CNS, Cardiovascular, Gastrointestinal/Metabolic, Oncology, Infectious Diseases and Other Therapeutic Areas, 2015-2016
  • 7.2. The Rise of Non-Communicable Diseases
  • 7.3. Market Forecast for CNS Conditions 2015-2026
    • 7.3.1. CNS Conditions Currently the Largest Therapeutic Area
    • 7.3.2. Domestic Companies Target Generic and OTC CNS Products
    • 7.3.3. Foreign Companies Target Analgesics Market
    • 7.3.4. One Fifth of Brazilians Have Suffered Depression
    • 7.3.5. CNS Conditions: Drivers and Restraints
  • 7.4. Market Forecast for Cardiovascular Therapeutic Area, 2015-2026
    • 7.4.1. Rate of Cardiovascular Disease Expected to Triple
    • 7.4.2. Almost One Quarter of the Population are Hypertensive
    • 7.4.3. Statin Revenues Decline with Loss of Patent Protection
    • 7.4.4. Domestic and International Companies Compete in CVS
    • 7.4.5. Cardiovascular Opportunities and Challenges
  • 7.5. Market Forecast for Gastrointestinal/Metabolic Therapeutic Area, 2015-2026
    • 7.5.1. High Prevalence of Diabetes and GI Conditions
    • 7.5.2. Low Awareness of Diabetes Amongst Population
    • 7.5.3. Drive for Domestic Production of Insulin
    • 7.5.4. EMS's Generic Esomeprazole an Important Addition
    • 7.5.5. Capturing the Gastrointestinal/Metabolic Disease Opportunity
  • 7.6. Market Forecast for Oncology Therapeutic Area, 2015-2026
    • 7.6.1. Cancer Treatment to Become the Leading Therapeutic Area
    • 7.6.2. Increased Coverage of Cancer Care by Private Health Insurance Providers
    • 7.6.3. What are the Commonest Cancers in Brazil?
    • 7.6.4. Biosimilars Will Help Widen Access to Cancer Drugs
    • 7.6.5. Cristália and Libbs Amongst Leading Oncology Companies
    • 7.6.6. Promising Potential of the Oncology Therapeutic Area
  • 7.7. Market Forecast for Infectious Diseases Therapeutic Area, 2015-2026
    • 7.7.1. Vaccines and Antibiotics Lead Therapeutic Area
    • 7.7.2. Brazil Increasingly Manufacturing its Own Vaccines
    • 7.7.3. First Vaccination Programme Against Dengue Fever
    • 7.7.4. Free Access to HIV Care Despite Concerns About Patent Protection
    • 7.7.5. Chagas Disease and Other Tropical Infections
    • 7.7.6. Long-Term Threat From Zika Virus Epidemic
    • 7.7.7. Importance of Infectious Diseases Compared to Chronic Diseases
  • 7.8. Market Forecast for Other Therapeutic Areas, 2015-2026

8. Domestic Companies in the Brazilian Market

  • 8.1. The Top Ten Domestic Pharmaceutical Companies in 2015
  • 8.2. Multinational Companies Still Own the Majority of the Market
  • 8.3. Domestic Sector Actively Encouraged by Government
  • 8.4. Domestic Firms Control 70% of Generics Market
  • 8.5. EMS: Brazil's Leading Pharmaceutical Company
    • 8.5.1. Separate Divisions for Different Drug Categories
    • 8.5.2. Full Production and R&D Capability
    • 8.5.3. Legrand and Germed are Key Subsidiaries
    • 8.5.4. Targeted Expansion Overseas
  • 8.6. Hypermarcas: Market Leader in OTC and Branded Generics
    • 8.6.1. Neo Quimica: Ranked Third in the Generics Segment
    • 8.6.2. Subsidiaries Include Mantecorp and Brainfarma
  • 8.7. Medley: Generics Company Owned by Sanofi
  • 8.8. Aché: A Major Acquisition Target in Brazil
    • 8.8.1. Anti-Inflammatory Acheflan Was First Drug Developed in Brazil
    • 8.8.2. Involvement of Aché in Acquisitions Process
    • 8.8.3. Part of Bionovis Collaboration
  • 8.9. Eurofarma: Fifth Largest Domestic Company with Plans to Cover 90% of Latin America
    • 8.9.1. Policy to Make Acquisitions in Latin America
  • 8.10. Teuto Operates Largest Pharmaceutical Complex in Latin America
    • 8.10.1. Melcon Partnership and Other Growth Strategies for Teuto
  • 8.11. Biolab Farmaceutica Leads Cardiology Drugs Market
    • 8.11.1. Partnering With German and Indian Companies
    • 8.11.2. Current Pipeline and Product Launches
  • 8.12. Cristalia: Largest Producer of Anaesthetics in Latin America
    • 8.12.1. Approval from ANVISA to Produce Biosimilar Drugs
    • 8.12.2. Leader in API Manufacturing
    • 8.12.3. Involved in One Third of all PDPs
  • 8.13. Libbs: Key Player in Cancer Treatment
    • 8.13.1. Libbs Secures $106m in Funding from BNDES for New Biotechnology Facility
  • 8.14. União Quimica: Huge Annual Production Capacity
    • 8.14.1. Agreement with Novartis and Possible Public Offering in 2015
  • 8.15. Other Domestic Players Include Laboratório Daudt Oliveira and Hebron
  • 8.16. Biosimilar Collaborations
    • 8.16.1. Bionovis: Conglomerate Developing 8 Biosimilars
    • 8.16.2. Orygen: Conglomerate Aiming to Develop 7 Biologics
    • 8.16.3. Other Biotech Players Include Biomm and Innova
    • 8.16.4. Fiocruz: At the Heart of Multiple PDPs
    • 8.16.5. ANVISA Reform of Brazilian Patent System

9. Multinational Companies in the Brazilian Market

  • 9.1. The Top Ten Multinational Pharmaceutical Companies in Brazil, 2015
  • 9.2. Notable M&A Activity
  • 9.3. Sanofi: Medley Purchase Makes French Giant the Outright Leader
    • 9.3.1. Group Companies Include Sanofi Pasteur and Genzyme
    • 9.3.2. Inventory Mishandling and Dip in 2013 Results
  • 9.4. Novartis: Only Multinational to Produce APIs in Brazil
    • 9.4.1. PDPs and a New $342m Biotechnology Facility in the North East
    • 9.4.2. Pricing and Reimbursement Solutions to Bring Costlier Drugs to Brazil
    • 9.4.3. Investment in Expansion Plans
  • 9.5. Roche: No Regrets About Staying in Brazil
    • 9.5.1. Oncology Opportunity and Herceptin Pricing
  • 9.6. Merck & Co. - Long-Standing Presence in the Brazilian Market
    • 9.6.1. Five Factories and Five Broad Therapeutic Areas
    • 9.6.2. Gardasil Added to SUS in 2013
    • 9.6.3. Joint Venture with Eurofarma and Cristalia
  • 9.7. Pfizer: Pursuing Strategy to Acquire Domestic Manufacturers
    • 9.7.1. Portfolio Ranges from Orphan Biologics to Multivitamins
  • 9.8. Takeda: Expanding its Brazilian Business
    • 9.8.1. Acquisitions of Nycomed and Multilab
  • 9.9. Bayer: Brazil is its Fifth Largest Market
    • 9.9.1. OTC is a Major Focus in Brazil
  • 9.10. AstraZeneca Targets Latin America
    • 9.10.1. Struggling with Loss of Exclusivity and Patent Infringement
  • 9.11. Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National Portfolio
    • 9.11.1. Looking to Acquire OTC Brands
    • 9.11.2. Technology Transfer Deal for Parkinson's Disease
  • 9.12. Merck KGaA Signed PDP with Bionovis for 8 Biosimilars
    • 9.12.1. Two Divisions and Multiple Therapeutic Fields
  • 9.13. Other Notable Multinationals in Brazil
    • 9.13.1. GSK: Vaccines and Technology Transfer Opportunities
    • 9.13.2. Abbott: Humira to Face Biosimilar Challenge in Brazil?
    • 9.13.3. Abbott: Generics and Diagnostics-Led Growth Strategy
    • 9.13.4. Eli Lilly: Investing in Upgrading Pharmaceutical Packaging Facility
    • 9.13.5. Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights
    • 9.13.6. Baxter Entering Haemophilia Market Via Technology Transfer
    • 9.13.7. Johnson & Johnson: Focusing on Consumer Health and Commodities
    • 9.13.8. BiocadBrazil Farmaceutica
    • 9.13.9. Amgen Signals Brazilian Intent with Bergamo Acquisition
    • 9.13.10. Gilead, Novo Nordisk, Biogen, UCB and Meizler
    • 9.13.11. Other Top Japanese Companies Trail Behind Takeda in Brazil
  • 9.14. Will Multinational Generics Leaders Compete in Brazil?
    • 9.14.1. Teva Targets Brazil
    • 9.14.2. Mylan Acquires Agila to Boost Brazilian Strategy
    • 9.14.3. Actavis May Target Brazil
    • 9.14.4. Ranbaxy and Daiichi Sankyo
    • 9.14.5. Torrent, Glenmark, Strides Arcolab and Biocon Looking to Brazil
    • 9.14.6. Valeant: M&A Drive Into the Market
  • 9.15. Brazil as a Pharmaceutical Research Destination

10. Qualitative Analysis of the Brazilian Pharmaceutical Market, 2016

  • 10.1. Strengths, Weaknesses, Opportunities and Threats (SWOT) Analysis
    • 10.1.1. A Crucial Market for the Pharmaceutical Industry
    • 10.1.2. Government Regulation Remains an Issue
    • 10.1.3. One of the Highest Pharmaceutical Tax Rates in the World
    • 10.1.4. Room to Expand in Therapeutic Areas and Geographic Regions
    • 10.1.5. Technology Transfer Uncertainties, IP Protection Doubts and Counterfeiting Issues
  • 10.2. Social, Technological, Economic and Political (STEP) Analysis
    • 10.2.1. Large and Ageing Population Eager to Buy Medicines
    • 10.2.2. Shortcomings of Brazil's Healthcare System
    • 10.2.3. Government Aims for Greater Self-Sufficiency in Biotechnology and Health IT
    • 10.2.4. Can Economic Growth Keep Pace with Healthcare Costs?
    • 10.2.5. Political Environment Acts as Decisive Influence on the Market
    • 10.2.6. Will BREXIT Affect Free Trade Negotiations with the EU?

11. Research Interviews

  • 11.1. Interview With Vitor Zani, Business Development Coordinator, BiocadBrazil Farmaceutica
    • 11.1.1. On Gaining Access to the Brazilian Market
    • 11.1.2. Factors That Differentiate Brazil From Other Markets
    • 11.1.3. The Brazilian Generics and Biosimilars Market and Biocad's Progress with Biosimilars
    • 11.1.4. Biocad's Brazilian Pipeline, its Progress in 2014 and its Prospects for the Future
    • 11.1.5. Development of the Brazilian Pharmaceutical Market 2015-2025; Drivers for Growth and Opportunity in the North East
    • 11.1.6. Effect of the 2014 World Cup on the Brazilian Pharmaceutical Market and How the 2016 Olympics Will Compare
    • 11.1.7. Strengths and Weaknesses of the Brazilian Pharmaceutical Market and Whether the Weaknesses Will Improve in Coming Years
  • 11.2. Interview with André Brazay, President of Sandoz Brazil
    • 11.2.1. Impact of Current Political and Economic Situation
    • 11.2.2. Challenges faced by Domestic Companies
    • 11.2.3. How Generics Market in Brazil Differs from Other Countries
    • 11.2.4. Importance of Biosimilars in Brazil
    • 11.2.5. Factors for an Overseas Investor to Consider
    • 11.2.6. Future Challenges for the Market in Brazil

12. Conclusions from Our Research and Analysis

  • 12.1. Growth of Brazil's Pharmaceutical Market Will Outstrip That of More Developed Countries
  • 12.2. Generics Will be Major Driver of Growth
  • 12.3. Technology Transfer Boosts Domestic Production of Originator Drugs
  • 12.4. Generics Market Provides Alternative Option for Multinationals
  • 12.5. Oncology is Leading Therapeutic and Commercial Opportunity
  • 12.6. Concluding Comments

List of Tables

  • Table 1.1: Sample Table: Brazilian Pharmaceutical Market Breakdown
  • Table 1.2: Currency Exchange Rates: Average Historic Exchange Rate to USD for 2014 and 2015
  • Table 2.1: Brazilian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 2.2: Brazilian Pharmaceutical Market by Segment: Revenue ($bn) and Market Share (%), 2015
  • Table 2.3: Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2015
  • Table 2.4: Brazilian Pharmaceutical Market: Top Ten Companies - Revenue ($bn) and Market Share (%), 2015
  • Table 3.1: World's Largest Pharmaceutical Markets, Revenue ($bn) and Market Share (%), 2015
  • Table 3.2: Top Latin American Pharmaceutical Markets: Revenue ($bn) and Market Share (%), 2015
  • Table 3.3: Pharmerging Countries
  • Table 4.1: Members of FenaSaúde (in Portuguese, with English in Brackets), 2016
  • Table 6.1: Originator Drug, Generic Drug and OTC Drug Segments Forecast: Revenue ($bn) and Market Share (%), 2015-2026
  • Table 6.2: Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn) and Market Share (%), 2021
  • Table 6.3: Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn) and Market Share (%), 2026
  • Table 6.4: Originator Drug, Generic Drug and OTC Drug Segments: Revenue Forecasts ($bn), 2015-2026
  • Table 6.5: Originator Drug Segment: Revenue Forecasts ($bn), 2015-2026
  • Table 6.6: Selected Technology Transfer Agreements in Brazil 1985-2013
  • Table 6.7: Generic Drug Segment: Revenue Forecasts ($bn), 2015-2026
  • Table 6.8: OTC Drug Segment: Revenue Forecasts ($bn), 2015-2026
  • Table 7.1: Brazilian Pharmaceutical Market - Therapeutic Areas: Revenue ($bn) and Market Share (%), 2015-2026
  • Table 7.2: Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2021
  • Table 7.3: Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn) and Market Share (%), 2026
  • Table 7.4: CNS Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026
  • Table 7.5: Cardiovascular Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026
  • Table 7.6: Gastrointestinal/Metabolic Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026
  • Table 7.7: Oncology Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026
  • Table 7.8: Infectious Diseases Therapeutic Area: Revenue ($bn) and Market Share (%), 2015-2026
  • Table 7.9: Other Therapeutic Areas: Revenue ($bn) and Market Share (%), 2015-2026
  • Table 8.1: Top Ten Domestic Pharmaceutical Companies in Brazil: Revenue ($bn) and Market Share (%), 2015
  • Table 8.2: EMS Overview
  • Table 8.3: Hypermarcas Overview
  • Table 8.4: Medley Overview
  • Table 8.5: Aché Overview
  • Table 8.6: Eurofarma Overview
  • Table 8.7: Teuto Overview
  • Table 8.8: Biolab Farmacêutica Overview
  • Table 8.9: Biolab Farmacêutica Pipeline, 2015
  • Table 8.10: Cristalia Overview
  • Table 8.11: Libbs Overview
  • Table 8.12: União Química Overview
  • Table 9.1: Leading Multinational Companies in the Brazilian Market: Revenues ($bn), Market Shares (%), 2015
  • Table 9.2: Selected Multinational M&A Activity in the Brazilian Market, 2009-2012
  • Table 9.3: Sanofi Overview
  • Table 9.4: Novartis Overview
  • Table 9.5: Roche Overview
  • Table 9.6: Merck & Co. Overview
  • Table 9.7: Pfizer Overview
  • Table 9.8: Takeda Overview
  • Table 9.9: Bayer Overview
  • Table 9.10: AstraZeneca Overview
  • Table 9.11: Boehringer Ingelheim Overview
  • Table 9.12: Merck KGaA Overview
  • Table 10.1: Brazilian Pharmaceutical Market: Strengths and Weaknesses, 2016
  • Table 10.2: Brazilian Pharmaceutical Market: Opportunities and Threats, 2016
  • Table 10.3: Brazilian Pharmaceutical Market: STEP Analysis, 2016

List of Figures

  • Figure 1.1: Product Segments of Brazilian Pharmaceutical Market
  • Figure 1.2: Main Therapeutic Areas Within the Brazilian Pharmaceutical Market
  • Figure 2.1: Brazilian Pharmaceutical Market: Revenue ($bn) 2015-2026
  • Figure 2.2: Brazilian Pharmaceutical Market by Segment: Market Share (%), 2015
  • Figure 2.3: Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2015
  • Figure 2.4: Brazilian Pharmaceutical Market: Top Ten Companies - Market Share (%), 2015
  • Figure 3.1: Top Ten Global Economies, 2015
  • Figure 3.2: Top Ten Global Economies, 2030
  • Figure 3.3: World's Largest Pharmaceutical Markets by Market Share (%), 2015
  • Figure 3.4: Top Latin American Pharmaceutical Markets: Market Share (%), 2015
  • Figure 3.5: BRIC Countries Pharmaceutical Market Revenue ($bn), 2015
  • Figure 4.1: Public Healthcare Versus Private Healthcare: Market Share (%), 2015
  • Figure 5.1: Doctors per 1,000 Inhabitants by Brazilian Region, 2013
  • Figure 5.2: Brazil: Regional Population Shares (%), 2013
  • Figure 5.3: Brazilian Pharmaceutical Market Shares (%) by Region, 2012
  • Figure 5.4: Brazilian GDP Shares (%) by Region, 2013
  • Figure 6.1: Originator Drug, Generic Drug and OTC Drug Segments: Market Share (%), 2021
  • Figure 6.2: Originator Drug, Generic Drug and OTC Drug Segments: Market Share (%), 2026
  • Figure 6.3: Originator Drug, Generic Drug and OTC Drug Segments: Revenue Forecasts ($bn), 2015-2026
  • Figure 6.4: Originator Drug, Generic Drug and OTC Drug Segments: Revenue ($bn), 2015, 2021, 2026
  • Figure 6.5: Originator Drug Segment: Revenue ($bn) 2015-2026
  • Figure 6.6: Drivers and Restraints for Patented Pharmaceuticals, 2016
  • Figure 6.7: Generic Drug Segment: Revenue ($bn) 2015-2026
  • Figure 6.8: Drivers and Restraints for Generic Drugs, 2016
  • Figure 6.9: Brazilian Biologics Market Breakdown: Revenue ($bn) and Market Share (%), 2015
  • Figure 6.10: Brazilian Biologics Market Breakdown: Revenue ($bn), 2015,2021, 2026
  • Figure 6.11: OTC Drug Segment: Revenue ($bn) 2015-2026
  • Figure 6.12: Drivers and Restraints for OTC Drugs, 2016
  • Figure 7.1: Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2021
  • Figure 7.2: Brazilian Pharmaceutical Market by Therapeutic Area: Market Share (%), 2026
  • Figure 7.3: Brazilian Pharmaceutical Market by Therapeutic Area: Revenue Forecasts ($bn), 2015-2026
  • Figure 7.4: Brazilian Pharmaceutical Market by Therapeutic Area: Revenue ($bn), 2015, 2021, 2026
  • Figure 7.5: CNS Therapeutic Area: Revenue ($bn), 2015-2026
  • Figure 7.6: Drivers and Restraints for CNS Conditions, 2016
  • Figure 7.7: Cardiovascular Therapeutic Area: Revenue ($bn), 2015-2026
  • Figure 7.8: Drivers and Restraints for the Cardiovascular Therapy Area, 2016
  • Figure 7.9: Gastrointestinal/Metabolic Therapeutic Area: Revenue ($bn), 2015-2026
  • Figure 7.10: Drivers and Restraints for Gastrointestinal/Metabolic Therapy Area, 2016
  • Figure 7.11: Oncology Therapeutic Area: Revenue ($bn) 2015-2026
  • Figure 7.12: Estimated Cancer Incidence for Males in Brazil, 2016
  • Figure 7.13: Estimated Cancer Incidence for Females in Brazil, 2016
  • Figure 7.14: Drivers and Restraints for the Oncology Therapeutic Area, 2016
  • Figure 7.15: Infectious Diseases Therapeutic Area: Revenue ($bn), 2015-2026
  • Figure 7.16: Drivers and Restraints for the Infectious Disease Therapeutic Area, 2016
  • Figure 7.17: Other Therapeutic Areas: Revenue ($bn), 2015-2026
  • Figure 8.1: Top Ten Domestic Pharmaceutical Companies in Brazil: Market Share (%), 2015
  • Figure 8.2: Aché Product Portfolio Breakdown (%), 2013
  • Figure 9.1: Leading Multinational Companies in the Brazilian Market: Market Shares (%), 2015
  • Figure 12.1: Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2015-2021
  • Figure 12.2: Brazilian Pharmaceutical Market: Overall Revenue ($bn), 2021-2026
  • Figure 12.3: Brazilian Pharmaceutical Market by Segment: Revenue ($bn), 2015-2021
  • Figure 12.4: Brazilian Pharmaceutical Market by Segment: Revenue ($bn), 2021-2026
  • Figure 12.5: Top Ten Companies in the Brazilian Pharmaceutical Market: Revenue ($bn), 2015
  • Figure 12.6: Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenue ($bn), 2015-2021
  • Figure 12.7: Brazilian Pharmaceutical Market Therapeutic Area Breakdown: Revenue ($bn), 2021-2026

Companies Listed

  • Abbott Laboratories
  • Aché Laboratórios Farmacêuticos S.A
  • Actavis PLC
  • Agência Nacional de Saúde Suplementar (ANS)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Agila Specialties Private Ltd
  • Allianz Saúde
  • Alteogen Inc
  • AMB (Brazilian Medical Association)
  • American Diabetes Association ADA)
  • AmerisourceBergen Corporation (ABC)
  • Amgen Inc
  • Antaris Consulting
  • Associação Brasileira das Redes de Farmácias e Drogarias (ABRAFARMA)
  • Associação Brasileira de Reabilitação de Coluna (Brazilian Association of Back Rehabilitation)
  • Associação da Industria Farmacêutica de Pesquisa (Interfarma)
  • Associação Nacional de Assistencia ao Diabetico (ANAD)
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Athos Farma SA
  • Axis Biotec Brasil
  • Baxter International Inc
  • Bayer AG
  • Bergamo Ltda
  • Beth Israel Hospital
  • Bill & Melinda Gates Foundation
  • Billi Farmacêutica
  • Biocad
  • BiocadBrazil Farmaceutica
  • Biocon Limited
  • Biolab Emcure Farmaceutica Comercial Ltda
  • Biolab Farmaceutica
  • Bio-Manguinhos (Instituta de Tecnologia em Imunobiologicos)
  • Biomm SA
  • Bionovis SA
  • Biovail Corporation
  • Boehringer Ingelheim GmbH
  • Boiron
  • Brainfarma Indústria Química e Farmacêutica
  • BrasilPharma
  • Brazil Produtos Roche Químicos e Farmacêuticos
  • Brazilian Institute of Tax Planning
  • Brazilian National Bank for Economic and Social Development (BNDES)
  • Brazilian National Institute of Social Security (INSS)
  • Bristol-Myers Squibb (BMS)
  • British Medical Journal (BMJ)
  • BTG Pactual
  • Bunker Industria Farmaceutica
  • Butantan Institute
  • Câmara de Regulação do Mercado de Medicamentos (CMED)
  • Care Plus Medicina Assistencial S/S Ltda
  • Ceitec SA
  • Celesio AG
  • Centre for Economics and Business Research (CEBR)
  • Chemo Group
  • Claris Lifesciences Ltd
  • Conselho Federal de Farmácia
  • Conselho Federal de Medicina (CFM)
  • Corporacion Infarmasa SA
  • Cosmed Industria de Cosmeticos e Medicamentos
  • Cristália
  • CVS Pharmacy
  • Daiichi Sankyo
  • Delta
  • Dimed SA
  • Distribuidora Farmacêutica Panarello Ltda
  • DM Industria Farmacêutica Ltda
  • Drogaria Sao Paulo
  • Drogarias DPSP SA
  • Drogarias Farmais
  • Drogarias Pacheco
  • Drogarias Tamoio
  • Drogasil SA
  • Eisai Co Ltd
  • Eli Lilly & Co
  • Emcure Pharmaceuticals Ltd
  • Empresas Andromaco
  • EMS
  • Eurofarma
  • Eurofarma Argentine
  • Eurofarma Chile
  • Eurofarma Uruguay
  • European Medicines Agency (EMA)
  • Everis Group
  • F. Hoffmann-La Roche AG
  • Farmácia Ben
  • Farmácia Popular
  • Farmacias Mais Econômica
  • Farmácias Guararapes
  • Farmalife
  • Farmanguinhos (Instituto de Tecnologia em Farmacos)
  • Farmindustria SA
  • Federação Nacional de Saúde Suplementar (FenaSaúde)
  • Federal Court of Rio de Janeiro
  • Food and Drug Administration (FDA)
  • Forest Laboratories Inc
  • Fundação Oswaldo Cruz (FioCruz)
  • Fundação Ezequiel Dias (Funed)
  • Genzyme Corporation
  • Germed Pharma
  • Gilead Sciences Inc
  • GlaxoSmithKline PLC (GSK)
  • Glenmark Pharmaceuticals
  • Golden Cross
  • Government of Brazil
  • Grünenthal Group
  • Grupo Amil Saúde
  • Grupo Bradesco Saúde
  • Grupo Cimed
  • Grupo Notre Dame Intermédica Saúde
  • Grupo SulAmérica Saúde
  • Hapvida Assistência Médica
  • Health Canada
  • Health Network Formation and Quality Improvement Project (QualiSUS)
  • Hebron
  • Hemobrás
  • Horizon Pharma PLC
  • Hospital das Clínicas, São Paulo
  • Hospital Israelita Albert Einstein
  • Hospital Santa Catarina
  • Hypermarcas
  • IMA Laboratories
  • Indar Institute
  • Indian Council of Medical Research
  • Innova Pharma
  • Institute for Health Insurance (IESS)
  • Instituto Brasileiro de Geografia e Estatística (IBGE)
  • Instituto de Estudos de Saúde Suplementar (IESS)
  • Instituto de Tecnologia do Paraná (TECPAR)
  • Instituto Terapeutico Delta
  • Instituto Vital Brazil
  • Janssen
  • Johnson & Johnson
  • Kantar Health
  • Kenya Medical Research Institute
  • Laboratório Daudt Oliveira
  • Laboratório Farmacutico do Estado de Pernambuco (LAFEPE)
  • Laboratório Prata
  • Laboratório Sanobiol
  • Laboratório Teuto
  • Laboratorio Volta
  • Laboratório Tiaraju
  • Laboratórios Gautier
  • Laboratórios Klinger Do Brasil
  • Laboratorios Laprin S.A
  • Lazard
  • Legrand Pharma Industria Farmaceutica Ltda
  • Libbs Biotec
  • Libbs Farmacêutica Ltda
  • Luper Indústria Farmacêutica
  • mAbxience
  • Mantecorp Quimica Industria e Farmaceutica Ltda
  • Médecins sans Frontières (MSF)
  • Medley Farmacêutica
  • Meizler Biopharma SA
  • Melcon Indústria Farmacêutica SA
  • Merck & Co., Inc
  • Merck KGaA
  • Merck Serono
  • Mercosur
  • Merial
  • Merz Pharma GmbH & Co. KGaA
  • Metlife Exclusivamente Odontológicos
  • Metropolitan Life Insurance Company
  • Minas Gerais State Department of Health
  • Ministry of Health of Malaysia
  • Ministry of Health, Brazil
  • Moksha8
  • Multilab Industria e Comerci de Produtos Farma
  • Mundipharma International Ltd
  • Mylan NV
  • National Institutes of Health
  • Nature's Plus Farmacêutica Ltda
  • NeoQuimica
  • Nortis Farmaceutica Ltda
  • Novartis AG
  • Novartis Biociências
  • Novo Nordisk A/S
  • Nycomed
  • OdontoPrev
  • Omint Serviços de Saúde
  • Oncoprod
  • Optimer Pharmaceuticals Inc
  • Organisation for Economic Co-operation and Development (OECD)
  • Orygen Biotecnologia
  • Otsuka Pharmaceutical Co Ltd
  • Pan American Health Organization
  • Panpharma
  • Pasteur Institute
  • Pele Nova Biotecnologia SA
  • Pfizer Inc
  • PharmaPraxis
  • Porto Seguro - Seguro Saúde
  • Probiomed SA de CV
  • Probiotica Laboratórios Ltda
  • Procter and Gamble Co
  • Profarma
  • Profarma Specialty SA
  • Pró-Genéricos (the Brazilian Association of Generic Drug Industries)
  • Protalix BioTherapeutics Inc
  • Quesada Farmacêutica SA
  • Quintiles Inc
  • Raia Drogasil
  • Raia SA
  • Ranbaxy Laboratories Ltd
  • Reckitt Benckiser Group PLC
  • Roche Diagnostica Brasil
  • Rosário
  • Sabin Vaccine Institute
  • Sandoz Brazil
  • Sandoz do Brasil Indústria Farmacêutica
  • Sanofi
  • Sanofi Pasteur SA
  • Sant'Ana S.A. Drogaria Farmácias
  • Santa Cruz Distribuidora de Medicamentos
  • São Paulo Stock Exchange
  • Savicevic Participacoes SA
  • SC Participações Empresariais Ltda
  • Schwarz Pharma
  • Serum Therapeutic Institute
  • Shasun Pharmaceuticals Ltd
  • Sinclair IS Pharma PLC
  • Sindicato do Comércio Atacadista de Drogas, Medicamentos, Correlatos, Perfumarias, Cosmeticos e Artigos de Toucador no Estado de São Paulo (SINCAMESP)
  • Sindusfarma
  • Sistema Único de Saúde (SUS)
  • State Pharmaceutical Laboratory of Pernambuco (LAFEPE)
  • Strides Arcolab
  • Sun Pharmaceutical Industries Ltd
  • Supera Farma Laboratorios
  • Takeda Pharmaceutical Company Ltd
  • Telefônica Digital
  • Teva Pharmaceutical Industries Ltd
  • The Walgreen Company
  • The Working Group on Intellectual Property of the Brazilian Network for the Integration of Peoples (GTPI/Rebrip
  • TKS Farmacêutica Ltda
  • Torrent Pharmaceuticals Ltd
  • UCB Pharma SA
  • UERJ (Universidade do Estado do Rio de Janeiro)
  • União Química Farmacêutica Nacional SA
  • UNICAMP (Universidade Estadual de Campinas)
  • Unimed Seguros Saúde
  • University of São Paulo
  • University of Texas
  • Valeant Pharmaceuticals International Inc
  • Walter Reed Army Institute of Research
  • Warc
  • Watson Pharmaceuticals Inc
  • Wockhardt Ltd
  • World Bank
  • World Health Organization (WHO)
  • Yasuda Marítima Saúde Seguros SA
  • Zydus Cadila
Back to Top